October 25, 2019

Sergio Traversa
Chief Executive Officer
Relmada Therapeutics, Inc.
880 Third Avenue, 12th Floor
New York, NY 10022

       Re: Relmada Therapeutics, Inc.
           Registration Statement on Form S-3
           Filed October 18, 2019
           File No. 333-234262

Dear Mr. Traversa:

       We have limited our review of your registration statement to those
issues we have
addressed in our comments. In some of our comments, we may ask you to provide
us with
information so we may better understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comments apply to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to these comments, we may have additional comments.

Registration Statement on Form S-3

Forum for Adjudication of Disputes, page 20

1.     Your forum selection provision identifies a Nevada state court as the
exclusive forum for
       certain litigation, including any "derivative action." We note your
disclosure that this
       provision applies to claims arising under the Securities Act and the
Exchange Act. Please
       note that Section 27 of the Exchange Act creates exclusive federal
jurisdiction over all
       suits brought to enforce any duty or liability created by the Exchange
Act or the rules and
       regulations thereunder. In response to the staff's comments on your
Registration Statement
       on Form S-1, File No. 333-233228, you disclosed that you did not intend
for the provision
       to apply to Exchange Act claims. If that is still true, please revise
this prospectus to
       clarify that you do not intend for the exclusive forum provision to
apply to Exchange Act
       claims.
 Sergio Traversa
Relmada Therapeutics, Inc.
October 25, 2019
Page 2
Incorporation of Documents by Reference, page 25

2.    We note that you have not incorporated by reference Exchange Act filings
made prior to
      the effective date of the registration statement. In that regard, please
revise to incorporate
      by reference your Current Report on Form 8-K filed on October 21, 2019.
Refer to
      Question 123.05 of the Securities Act Forms Compliance and Disclosure
Interpretations.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Ada D. Sarmento at 202-551-3798 or Celeste Murphy at
202-551-3257
with any questions.



                                                             Sincerely,
FirstName LastNameSergio Traversa
                                                             Division of
Corporation Finance
Comapany NameRelmada Therapeutics, Inc.
                                                             Office of Life
Sciences
October 25, 2019 Page 2
cc:       Thomas R. Slusarczyk, Esq.
FirstName LastName